Astria Therapeutics, Inc. (ATXS)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Astria Therapeutics, Inc. (ATXS)
Go deeper and ask any question about ATXS
Company Performance
Current Price
as of Sep 13, 2024$11.14
P/E Ratio
N/A
Market Cap
$628.58M
Description
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.
Metrics
Overview
- HQBoston, MA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerATXS
- Price$11.14+4.90%
Trading Information
- Market Cap$628.58M
- Float84.00%
- Average Daily Volume (1m)278,228
- Average Daily Volume (3m)373,340
- EPS-$2.30
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$24.17M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$28.80M
- EV$260.27M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
Documents
SEC Filings
Factset Street Account